6
.
what
uva
radiation
doses
are
appropriate
for
use
in
the
ipd
test
?
7
.
when
should
the
ipd
response
be
readimmediately
,
or
1
or
2
hours
after
uva
exposure
?
8
.
is
the
ipd
reaction
relevant
to
protection
of
the
skin
from
uva
damage
?
9
.
do
the
available
data
demonstrate
that
the
ipd
test
is
stable
,
nonvariable
,
and
reproducible
?
identify
the
data
.
10
.
do
the
available
data
demonstrate
that
the
ipd
testing
response
obeys
dose
reciprocity
over
the
anticipated
irradiance
range
?
11
.
are
results
of
the
pfa
testing
procedure
relevant
to
protection
of
the
skin
from
uva
damage
?
identify
the
results
.
12
.
do
the
data
show
that
the
pfa
test
obeys
dose
reciprocity
?
identify
the
data
.
13
.
can
the
interval
after
exposure
at
which
pfa
responses
are
read
affect
the
results
?
14
.
does
the
heat
or
infrared
energy
delivered
to
the
skin
during
pfa
testing
exposure
affect
the
results
?
15
.
describe
the
specifications
for
an
appropriate
light
source
for
the
pfa
testing
method
,
eg
,
spectral
distribution
,
intensity
,
etc
.
the
agency
has
concluded
,
under
21
cfr
10
65
,
that
it
would
be
in
the
public
interest
to
hold
a
public
meeting
to
discuss
the
many
questions
and
topics
associated
with
uva
testing
for
otc
sunscreen
drug
products
.
the
proposed
rulemaking
involves
21
cfr
parts
352
,
700
,
and
740
;
however
,
the
discussion
at
the
public
meeting
will
be
limited
to
part
352
.
the
agency
requests
information
regarding
uva
protection
claims
and
uva
testing
procedures
from
any
interested
person
.
however
,
the
agency
requests
that
only
new
or
additional
information
not
previously
included
in
the
rulemaking
be
submitted
.
data
should
be
specifically
limited
and
relevant
to
the
questions
asked
.
any
individual
or
group
may
,
on
or
before
04/29/1994
,
submit
to
the
dockets
management
branch
(
address
above
,
comments
and
data
relevant
to
the
questions
and
topics
on
uva
protection
and
testing
procedures
contained
in
this
document
.
two
copies
of
any
comments
are
to
be
submitted
,
except
that
individuals
may
submit
one
copy
.
all
comments
are
to
be
identified
with
the
docket
number
found
in
brackets
in
the
heading
of
this
document
.
it
is
not
necessary
to
resubmit
data
and
information
submitted
previously
to
this
docket
.
any
individual
or
group
interested
in
making
a
presentation
at
the
meeting
should
contact
jeanne
rippere
(
address
above
.
presentations
should
only
address
the
questions
and
topics
listed
previously
.
persons
interested
in
participating
in
the
meeting
must
also
send
a
notice
of
participation
on
or
before
04/29/1994
,
to
the
dockets
management
branch
(
address
above
.
all
notices
of
participation
submitted
should
be
identified
with
the
docket
number
found
in
brackets
in
the
heading
of
this
document
and
should
contain
the
following
information
:
name
,
address
,
telephone
number
,
business
affiliation
,
if
any
,
of
the
person
desiring
to
make
a
presentation
,
summary
of
the
presentation
,
and
the
approximate
amount
of
time
requested
for
the
presentation
.
groups
having
similar
interests
are
requested
to
consolidate
their
comments
and
present
them
through
a
single
representative
.
depending
on
the
time
available
and
the
number
of
participants
,
fda
may
require
joint
presentations
by
persons
with
common
interests
.
after
reviewing
the
notices
of
participation
,
fda
will
notify
each
participant
of
the
schedule
and
time
allotted
to
each
person
.
the
administrative
record
for
the
otc
sunscreen
drug
products
rulemaking
is
being
reopened
to
specifically
include
only
the
proceedings
of
this
public
meeting
.
the
administrative
record
will
remain
open
until
07/31/1994
,
to
allow
comments
on
matters
raised
at
the
meeting
.
references
(
1
)
letters
from
w
.
e
.
gilbertson
,
fda
,
to
t
.
p
.
koestler
,
westwood
pharmaceuticals
,
inc
,
k
.
m
.
obrien
,
scheringplough
schering
plough
corp
,
n
.
j
.
lowe
,
ucla
school
of
medicine
,
and
m
.
a
.
pathak
,
harvard
medical
school
,
coded
let45
,
let47
,
let50
,
and
let52
,
respectively
,
in
docket
no
.
78n0038
,
dockets
management
branch
.
(
2
)
lowe
,
n
.
j
.
et
al
,
`
indoor
and
outdoor
efficacy
testing
of
a
broad
spectrum
sunscreen
against
ultraviolet
a
radiation
in
psoralensensitized
psoralen
sensitized
subjects
'
journal
of
the
american
academy
of
dermatology
,
17224230
,
1987
.
(
3
)
mckinlay
,
a
.
f
,
and
b
.
l
.
diffey
,
`
a
reference
action
spectrum
for
ultraviolet
induced
erythema
in
human
skin
'
cie
journal
,
61722
,
1987
.
(
4
)
comment
no
.
c104
,
docket
no
.
78n0038
,
dockets
management
branch
.
(
5
)
reference
29
,
comment
no
.
c128
,
docket
no
.
78n0038
,
dockets
management
branch
.
(
6
)
reference
30
,
comment
no
.
c128
,
docket
no
.
78n0038
,
dockets
management
branch
.
(
7
)
figure
2
,
comment
no
.
c128
,
docket
no
.
78n0038
,
dockets
management
branch
.
(
8
)
comment
no
.
135
,
docket
no
.
78n0038
,
dockets
management
branch
.
(
9
)
sayre
,
r
.
m
.
et
al
,
`
a
comparison
of
in
vivo
and
in
vitro
testing
of
sunscreening
formulas
'
photochemistry
and
photobiology
,
29559566
,
1979
.
<
text
>
